A comparative study of gemcitabine plus cisplatin and gemcitabine plus carboplatin in advanced urothelial carcinoma

Real world comparison of gemcitabine cisplatin and gemcitabine carboplatin for advanced urothelial carcinoma prognostic factors and clinical implications - N/A

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060158

Enrollment

Registered

2025-12-22

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced urothelial carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Histologically confirmed urothelial carcinoma - Locally advanced or metastatic urothelial carcinoma - Received gemcitabine plus cisplatin or gemcitabine plus carboplatin as first line systemic chemotherapy

Exclusion criteria

Exclusion criteria: - Patients who received initial systemic chemotherapy other than gemcitabine plus cisplatin or gemcitabine plus carboplatin - Patients with active concomitant malignancies other than urothelial carcinoma - Patients with insufficient clinical data prior to treatment initiation

Design outcomes

Primary

Measure	Time frame
Overall survival (OS) Defined as the time from initiation of chemotherapy to death from any cause.	—

Secondary

Measure	Time frame
Progression-free survival (PFS) Defined as the time from initiation of chemotherapy to radiological or clinical disease progression, or death from any cause. Objective response rate (ORR) Defined as the proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST version 1.1. Exploratory analysis of prognostic factors for overall survival To evaluate the association between clinical factors, including inflammatory and nutritional markers, and overall survival.	—

Measure

Time frame

Progression-free survival (PFS) Defined as the time from initiation of chemotherapy to radiological or clinical disease progression, or death from any cause. Objective response rate (ORR) Defined as the proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST version 1.1. Exploratory analysis of prognostic factors for overall survival To evaluate the association between clinical factors, including inflammatory and nutritional markers, and overall survival.

—

Countries

Japan

Contacts

Public ContactTakeshi Hashimoto

Tokyo Medical University Hachioji Medical Center Department of Urology

ha-tkc@tokyo-med.ac.jp+81-42-665-5611

Outcome results